Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06351579
Other study ID # 1010159
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 15, 2024
Est. completion date March 15, 2026

Study information

Verified date April 2024
Source Levee Medical, Inc.
Contact Karen Cornett
Phone 7046576278
Email kcornett@leveemedical.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study is to collect information on patients undergoing radical prostatectomy (RP), with a primary focus on the occurrence, duration, and severity of post-prostatectomy incontinence. Data will be collected at multiple time points, allowing for a dynamic understanding of urinary incontinence patterns at post RP.


Description:

Urinary incontinence is predominantly iatrogenic following radical prostatectomy (RP). Surgical removal of the prostate leads to a shortened urethra, widened bladder neck, and diminished urethral support. This results in increased demand on the urinary sphincter to maintain urinary continence. Most men will experience acute urinary incontinence following RP. Continence progressively improves over time; however, it is estimated that between 5-15% of men will experience chronic urinary incontinence. Current treatments for post-prostatectomy urinary incontinence include conservative therapies such as pelvic floor muscle training and surgical treatments. This study is to systematically collect detailed information on patients undergoing radical prostatectomy, with a primary focus on the occurrence, duration, and severity of post-prostatectomy incontinence. Data will be collected at multiple time points, allowing for a dynamic understanding of urinary incontinence patterns at post RP.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date March 15, 2026
Est. primary completion date December 30, 2025
Accepts healthy volunteers No
Gender Male
Age group 45 Years to 70 Years
Eligibility Inclusion Criteria: 1. Male 45-70 years of age 2. Diagnosed with prostate cancer and scheduled for radical prostatectomy 3. Gleason Grade Group 3 or lower 4. Prostate size less than 80 grams 5. Able and willing to provide written consent to participate in the study 6. Able and willing to comply with study follow-up visits and procedures Exclusion Criteria: 1. Malignant tumors outside of the prostate capsule confirmed via baseline assessments (e.g., mpMRI, bone scan) 2. History of urinary incontinence, including stress or urge urinary incontinence 3. On medications to treat overactive bladder (OAB) 4. Presence of urethral stricture or bladder neck contracture 5. Current or chronic urinary tract infection 6. Prior urologic outlet surgical or minimally invasive procedure (e.g., TURP, HoLEP, Rezum, etc.). 7. Prior pelvic radiation or anticipated need for radiation after radical prostatectomy 8. Presence of stones in the bladder 9. History of neurogenic bladder, sphincter abnormalities, or poor detrusor muscle function 10. Body mass index >35 11. History of cancer (excluding prostate cancer meeting the inclusion criteria) which is not considered in complete remission - a potential participant is considered cured if there has been no evidence of cancer within five years of enrollment 12. Diagnosed or suspected primary neurologic conditions such as multiple sclerosis or Parkinson's disease or other neurological diseases known to affect bladder function, sphincter function or poor detrusor muscle function 13. History of clinically significant congestive heart failure (i.e., New York Heart Association (NYHA) Class III and IV) 14. Insulin-dependent diabetes mellitus 15. Current uncontrolled diabetes (i.e., hemoglobin A1c =7.5%) 16. Intravesical prostatic protrusion (IPP) >5mm 17. History of immunosuppressive conditions (e.g., AIDS, post-transplant) 18. Any significant medical history that would pose an unreasonable risk or make the subject unsuitable for the study per investigator discretion 19. Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affect the ability to complete the study quality of life questionnaires 20. Subject currently participating in other investigational studies unless approved by the Sponsor in writing

Study Design


Intervention

Other:
Control
This is an observational (registry) study for data collection only. No device or intervention will be used in this study.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Levee Medical, Inc. RQMplus

Outcome

Type Measure Description Time frame Safety issue
Other Expanded Prostate Index Composite (EPIC-26) score. The Expanded Prostate Cancer Index Composite is a validated, comprehensive questionnaire designed to evaluate patient function and bother after localized prostate cancer treatment. The questionnaire contains 13 items across 5 domains (i.e., urinary incontinence, urinary irritative/obstructive, bowel, sexual and hormonal). Response options for each item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better quality of life. Baseline, post-foley, 6 weeks, 3 months, 6 months, and 12 months post-prostatectomy procedure.
Primary The change in average 24-hour pad weight over time The 24-hour (at-home) pad weight test - The pads are pre-weighed prior to providing them to subjects. The test should be started with an empty bladder. The subject will wear pads and perform their normal daily activities for 24 hours. The subject will be asked to change the pads approximately once every 6 hours during waking hours, or more frequently as needed. The pads will be stored in an air tight bag or container after removal, stored in a refrigerator, and brought to the site at the required follow-up visit for weighing. Baseline, post-foley, 6 weeks, 3 months, 6 months, and 12 months post-prostatectomy procedure.
Secondary Change in pad weight during a 1-hour provocative pad weight test The 1-hour pad test involves the following:
Subject puts on a pre-weighed pad and is asked to avoid voiding;
Subject drinks 500 ml of sodium-free liquid in <15 minutes, then sits or rests;
Subjects walks for 30 minutes, including climbing one flight of stairs (up and down)
Subject performs the following activities: standing up from sitting (10x), coughing vigorously (10x), running on the spot for 1 minute, bending to pick up an object from the floor (5x), and washing hands in running water for 1 minute;
The total amount of urine leaked is determined by weighing the pad. If voiding is urgent and unavoidable, the test is terminated. Collect voiding volume and repeat the test after re-hydration.
Baseline, post-foley, 6 weeks, 3 months, 6 months, and 12 months post-prostatectomy procedure.
See also
  Status Clinical Trial Phase
Recruiting NCT04829357 - Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT04512053 - A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence Phase 2
Active, not recruiting NCT06224335 - Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
Recruiting NCT05304312 - The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women N/A
Not yet recruiting NCT05527665 - Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
Not yet recruiting NCT04558762 - Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
Withdrawn NCT02524366 - A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement N/A
Completed NCT01924728 - Efficacy of Magnetic Stimulation for Stress Urinary Incontinence N/A
Completed NCT01676662 - Solace European Confirmatory Trial N/A
Unknown status NCT01455779 - Lyrette: Renewing Continence Objective and Subjective Efficacy Study N/A
Terminated NCT01029106 - Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI) N/A
Completed NCT01770691 - Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence N/A
Completed NCT01123096 - Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence? N/A
Withdrawn NCT00573703 - Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence Phase 4
Completed NCT00234754 - Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women N/A
Completed NCT00441454 - Retropubic vs. Transobturator Tension-free Vaginal Tape N/A
Completed NCT03985345 - Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence. N/A
Active, not recruiting NCT03671694 - Laser Vaginal Treatment for SUI N/A
Completed NCT04097288 - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Phase 1